Ownership and insider activity for Disc Medicine, Inc. (IRON): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases.
Price
| Price | $78.62 (closing price, November 2, 2026) |
| Market Cap | $3.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-19 | Bitterman Kevin | S-Sale | 5,937 | $475K |
| 2026-10-20 | Bitterman Kevin | S-Sale | 2,869 | $229K |
| 2026-10-19 | Bitterman Kevin | S-Sale | 4,942 | $395K |
| 2026-10-20 | Bitterman Kevin | S-Sale | 2,388 | $191K |
| 2026-10-21 | Bitterman Kevin | S-Sale | 13,783 | $1.1M |
| 2026-10-21 | Bitterman Kevin | S-Sale | 11,470 | $920K |
| 2026-10-19 | Bitterman Kevin | S-Sale | 115 | $9K |
| 2026-10-20 | Bitterman Kevin | S-Sale | 55 | $4K |
| 2026-10-21 | Bitterman Kevin | S-Sale | 266 | $21K |
| 2026-09-15 | Quisel John D | M-Exempt | 36,000 | $36K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.5M | $88.0M | $194.6M | $360.4M | $192.4M | $91.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | $297.4M | $700.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.1M | $90.5M | $198.5M | $365.7M | $493.6M | $803.9M |
| Property, Plant & Equipment | $294,000 | $1.7M | $1.6M | $2.1M | $2.3M | $2.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $8.3M | $92.4M | $200.2M | $368.0M | $496.8M | $806.9M |
| Accounts Payable | $2.4M | $2.6M | $16.2M | $12.6M | $7.9M | $9.0M |
| Short-term Debt | $16.7M | $5.0M | 0 | 0 | 0 | $611,000 |
| Total Current Liabilities | $24.9M | $13.4M | $22.6M | $21.4M | $23.3M | $36.6M |
| Long-term Debt | $5.0M | $404,000 | 0 | 0 | $28.3M | $1.3M |
| Total Liabilities | $30.2M | $156.6M | $23.6M | $22.9M | $53.2M | $67.1M |
| Retained Earnings | -$112.8M | -$65.4M | -$112.2M | -$188.6M | -$298.0M | -$510.2M |
| Total Equity | -$21.9M | -$64.2M | $176.6M | $345.1M | $443.6M | $739.8M |
| Total Debt | $21.6M | $7.1M | $1.3M | $2.1M | $30.0M | $1.9M |
| Net Debt | $17.1M | -$81.0M | -$193.3M | -$358.3M | -$459.9M | -$789.3M |
| Working Capital | -$19.8M | $77.1M | $175.9M | $344.2M | $470.3M | $767.3M |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 24.14 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 24.37 |
Profitability
| Return on Equity | -37.17% |
| Return on Invested Capital | -38.19% |
| Return on Assets | -33.45% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: PTGX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IRON: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks